Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR1018B
- Development stage
- Phase 3
- Lead developer
- Boryung
- Modality
- Small Molecules
01
Overview
BR1018B is a small molecule drug under development by Boryung Corp. for the treatment of essential hypertension and primary hypercholesterolemia. It is being studied both as a monotherapy and in combination with other investigational agents (such as BR1018C) in phase 3 clinical trials targeting patients with coexisting high blood pressure and elevated cholesterol levels. The precise mechanism of action, molecular target(s), and active ingredient(s) have not been publicly disclosed as of June 2025, but it is positioned within the cardiovascular and metabolic disease therapeutic areas[1][2][4].
- Brand names
- BR1018BBR-1018BBR 1018B
- Other names
- BR1018BBR-1018BBR 1018B
Beyond the preview
Go deeper on BR1018B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR1018B.